hit counter
Adial Pharmaceuticals, Inc. (ADIL) Stock News Sentiment & Price - Sentifly
ADIL - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Adial Pharmaceuticals, Inc. (ADIL)

USA
Biotechnology
NASDAQ
ADIL Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ADIL Latest news
Benzinga
Neutral
Adial Pharma-Backed Purnovate Selects PNV-5030 As Pain Management Candidate
2021-10-21 13:06

Adial Pharmaceuticals Inc (NASDAQ: ADIL) has announced data in a preclinical model of pain reduction. Based on the data, Adial's subsidiary Purnovate Inc selected PNV-5030 as the lead compound for its program to develop pain management drugs.

GlobeNewsWire
Neutral
Adial Announces Positive Pre-Clinical Data for Purnovate's PNV-5030 as a Drug Candidate for the Treatment of Pain
2021-10-21 10:13

Results suggest potential of PNV-5030 as both a standalone and combination therapy  to reduce or eliminate opioid use and achieve meaningful pain reduction

GlobeNewsWire
Neutral
Adial Announces Positive Pre-Clinical Data for Purnovate's PNV-5030 as Drug Candidate for the Treatment of Pain
2021-10-21 09:45

Results suggest potential of PNV-5030 as both a standalone and combination therapy  to reduce or eliminate opioid use and achieve meaningful pain reduction

Accesswire
Neutral
Adial Pharmaceuticals to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Tuesday, October 5, 2021
2021-10-05 09:25

CHARLOTTESVILLE, VA / ACCESSWIRE / October 5, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the Company has been invited to present at the Fall Harvest - Best Ideas from the Buy-Side conference, which is being held virtually this week, October 5 - 8, 2021. William Stilley, Chief Executive Officer and President of Adial Pharmaceuticals, will present at the conference.

GlobeNewsWire
Neutral
Adial CEO William Stilley Invited to Participate in Maxim Group's Virtual Panel Series Conference: “Disruptors in the Mental Health Space”
2021-09-15 10:07

CHARLOTTESVILLE, Va., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals, has been invited to participate in Maxim Group's virtual panel series conference: "Disruptors in the Mental Health Space," which will be taking place on Wednesday, September 22, 2021 from 9:00am-3:00pm ET.

GlobeNewsWire
Neutral
Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-07 09:00

CHARLOTTESVILLE, Va., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021.

GlobeNewsWire
Neutral
Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04
2021-08-10 09:30

CHARLOTTESVILLE, Va., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided an update on recently issued patents for the use of Adial's lead asset, AD04, for the treatment of both Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD). AD04 is currently being evaluated in the Company's ONWARD trial, a Phase 3 clinical study to evaluate the efficacy, safety and tolerability of AD04 in patients with AUD, which is being conducted in seven countries.

GlobeNewsWire
Neutral
Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform
2021-07-14 14:00

Data merits further testing for pain reduction as a possible alternative to opioids

GlobeNewsWire
Neutral
The Phase 3 ONWARD™ Trial Meets its Screening Target and Nears Enrollment Completion
2021-07-06 09:25

Study Drug Continues to Appear to be Well-Tolerated

Loading more news...